Should I buy or sell Biogen stock right now?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 9 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIIB shares. View BIIB analyst ratings or view top-rated stocks .

What is Biogen's stock price target for 2024?

27 Wall Street research analysts have issued 12-month price objectives for Biogen's shares. Their BIIB share price targets range from $213.00 to $373.00. On average, they anticipate the company's stock price to reach $295.58 in the next year. This suggests a possible upside of 53.0% from the stock's current price. View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts .

How have BIIB shares performed in 2024?

Biogen's stock was trading at $258.77 on January 1st, 2024. Since then, BIIB shares have decreased by 25.3% and is now trading at $193.18. View the best growth stocks for 2024 here .

Are investors shorting Biogen?

Biogen saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,550,000 shares, an increase of 33.5% from the March 15th total of 2,660,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.5% of the company's shares are short sold. View Biogen's Short Interest .

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our BIIB earnings forecast .

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Wednesday, April 24th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its earnings results on Tuesday, February, 13th. The biotechnology company reported $2.95 EPS for the quarter, missing analysts' consensus estimates of $3.18 by $0.23. The biotechnology company had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.47 billion. Biogen had a net margin of 11.81% and a trailing twelve-month return on equity of 14.91%. During the same period in the prior year, the business earned $4.05 EPS. Read the conference call transcript .

What ETFs hold Biogen's stock?

ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , VanEck Biotech ETF (BBH) , iShares Neuroscience and Healthcare ETF (IBRN) , Subversive Mental Health ETF (SANE) , Horizon Kinetics Medical ETF (MEDX) , Invesco Pharmaceuticals ETF (PJP) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Invesco Nasdaq Biotechnology ETF (IBBQ) .

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY24 earnings guidance on Wednesday, April, 24th. The company provided earnings per share (EPS) guidance of $15.00-16.00 for the period, compared to the consensus estimate of $15.49. The company issued revenue guidance of decline low- to mid-single digits, compared to the consensus revenue estimate of $9.47 billion.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com . Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , Netflix (NFLX) , Tesla (TSLA) , Alibaba Group (BABA) , Amgen (AMGN) , Walt Disney (DIS) , Intel (INTC) , Micron Technology (MU) and Boeing (BA) .

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.27%), Raymond James & Associates (0.12%), Saratoga Research & Investment Management (0.11%), Grimes & Company Inc. (0.03%), Assenagon Asset Management S.A. (0.03%) and Gateway Investment Advisers LLC (0.03%). Insiders that own company stock include Alfred Sandrock , Brian S Posner , Eric K Rowinsky, Ginger Gregory, Priya Singhal and Susan H Alexander . View institutional ownership trends .

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited. Read More

Most-Downgraded StocksMost-Downgraded

NASDAQ:BIIB

Biogen (BIIB) Stock Price, News & Analysis

→ At first glance, this chart looks like nonsense… (From The TradingPub) (Ad)

Free BIIB Stock Alerts

$193.18

-0.93 (-0.48%)

(As of 04/23/2024 ET)

Compare

Today's Range: $192.75
▼
$195.86
50-Day Range: $190.52
▼
$230.07
52-Week Range: $189.44
▼
$319.76

Volume: 1.46 million shs
Average Volume: 1.11 million shs
Market Capitalization: $28.08 billion

P/E Ratio: 24.21
Dividend Yield: N/A
Price Target: $295.58

Get Biogen alerts:

Biogen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 53.0% Upside
$295.58 Price Target
Short Interest: Healthy
2.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.65
Upright™ Environmental Score
News Sentiment: 0.09
Based on 49 Articles This Week
Insider Trading: Selling Shares
$202,030 Sold Last Quarter
Proj. Earnings Growth: 12.08%
From $15.48 to $17.35 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.93 out of 5 stars

Medical Sector

16th out of 909 stocks

Biological Products, Except Diagnostic Industry

4th out of 156 stocks

4.3

Analyst's Opinion

Consensus Rating
Biogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 18 buy ratings, 9 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Biogen has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
2.46% of the float of Biogen has been sold short.
Short Interest Ratio / Days to Cover
Biogen has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biogen has recently increased by 33.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biogen does not currently pay a dividend.
Dividend Growth
Biogen does not have a long track record of dividend growth.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Biogen has received a 40.57% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Multiple sclerosis medication", "Interferons", and "Biopharmaceuticals" products. See details.
Environmental Sustainability
The Environmental Impact score for Biogen is -2.65.

2.8

News and Social Media Coverage

News Sentiment
Biogen has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 49 news articles for Biogen this week, compared to 16 articles on an average week.
Search Interest
42 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.
MarketBeat Follows
41 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 116% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biogen insiders have sold 99.52% more of their company's stock than they have bought. Specifically, they have bought $101,256.00 in company stock and sold $202,030.00 in company stock.
Percentage Held by Insiders
Only 0.60% of the stock of Biogen is held by insiders.
Percentage Held by Institutions
87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Biogen are expected to grow by 12.08% in the coming year, from $15.48 to $17.35 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biogen is 24.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biogen is 24.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 167.00.
Price to Earnings Growth Ratio
Biogen has a PEG Ratio of 1.85. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Biogen has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

Click To Access This Powerful Training Right Now!

About Biogen Stock (NASDAQ:BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIIB Stock News Headlines

April 4, 2024 | insidertrades.com

Biogen Inc. (NASDAQ:BIIB) Insider Sells $19,817.37 in Stock

April 24, 2024 | seekingalpha.com

Biogen says uptake for Alzheimer’s therapy is improving

April 24, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

April 24, 2024 | reuters.com

Biogen beats quarterly profit estimates, Alzheimer's drug sales jump

April 24, 2024 | cnbc.com

Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up

April 23, 2024 | reuters.com

Insight: Alzheimer's drug adoption in US slowed by doctors' skepticism

April 23, 2024 | americanbankingnews.com

Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Moderate Buy" by Brokerages

April 23, 2024 | finance.yahoo.com

Should You Be Confident in Biogen (BIIB)?

April 24, 2024 | WealthPress (Ad)

The system that called 2023’s top 7 stocks is at it again…

Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.

April 21, 2024 | americanbankingnews.com

Oppenheimer Lowers Biogen (NASDAQ:BIIB) Price Target to $270.00

April 21, 2024 | nasdaq.com

Biogen Inc. Common Stock (BIIB)

April 20, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Cut by William Blair

April 20, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for Biogen Inc. Reduced by Wedbush (NASDAQ:BIIB)

April 19, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)

April 19, 2024 | forbes.com

Pfizer On The New Lows List. Big Dividend Fails To Attract Buyers.

April 19, 2024 | baystreet.ca

Today's Biggest Losers

April 19, 2024 | americanbankingnews.com

Wedbush Lowers Biogen (NASDAQ:BIIB) Price Target to $213.00

April 19, 2024 | americanbankingnews.com

Biogen (NASDAQ:BIIB) Price Target Cut to $214.00

April 19, 2024 | americanbankingnews.com

Q3 2024 Earnings Forecast for Biogen Inc. Issued By Wedbush (NASDAQ:BIIB)

April 18, 2024 | benzinga.com

Biogen Unusual Options Activity For April 18

April 18, 2024 | americanbankingnews.com

Biogen (NASDAQ:BIIB) Reaches New 12-Month Low at $195.06

April 17, 2024 | finance.yahoo.com

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

April 17, 2024 | americanbankingnews.com

Biogen (BIIB) to Release Quarterly Earnings on Wednesday

April 16, 2024 | msn.com

Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report

April 16, 2024 | finance.yahoo.com

Biogen Inc. (BIIB) Interactive Stock Chart - Yahoo Finance

April 14, 2024 | americanbankingnews.com

Bank of America Cuts Biogen (NASDAQ:BIIB) Price Target to $260.00

April 12, 2024 | finance.yahoo.com

Biogen Is Suffering From Doubts About the Future

See More Headlines

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/24/2024
Next Earnings (Confirmed): 4/24/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:BIIB
CUSIP: 09062X10
CIK: 875045
Web: www.biogen.com
Phone: (617) 679-2000
Fax: 617-679-2617
Employees: 7,570
Year Founded: 1978

Price Target and Rating

Average Stock Price Target: $295.58
High Stock Price Target: $373.00
Low Stock Price Target: $213.00
Potential Upside/Downside: +53.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 27 Analysts

Profitability

EPS (Most Recent Fiscal Year): $7.98
Trailing P/E Ratio: 24.21
Forward P/E Ratio: 12.48
P/E Growth: 1.85
Net Income: $1.16 billion
Net Margins: 11.81%
Pretax Margin: 13.19%
Return on Equity: 14.91%
Return on Assets: 8.18%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 2.00
Quick Ratio: 1.26

Sales & Book Value

Annual Sales: $9.84 billion
Price / Sales: 2.86
Cash Flow: $18.35 per share
Price / Cash Flow: 10.53
Book Value: $102.14 per share
Price / Book: 1.89

Miscellaneous

Outstanding Shares: 145,360,000
Free Float: 144,489,000
Market Cap: $28.08 billion
Optionable: Optionable
Beta: -0.02

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Christopher A. Viehbacher (Age 63)
President, CEO & Director
Comp: $487.94k
Mr. Michael R. McDonnell CPA (Age 60)
Executive VP & CFO
Comp: $2.12M
Ms. Nicole Murphy
Head of Pharmaceutical Operations & Technology
Ms. Susan H. Alexander Esq. (Age 67)
Executive VP & Chief Legal Officer
Comp: $2.2M
Dr. Ginger Gregory (Age 56)
Executive VP & Chief Human Resources Officer
Comp: $1.59M
Ms. Robin C. Kramer (Age 58)
Senior VP & Chief Accounting Officer
Mr. Charles E. Triano
Senior VP & Head of Investor Relations
Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corporate Affairs
Mr. Adam Keeney Ph.D.
Executive VP & Head of Corporate Development
Ms. Alisha A. Alaimo
President & Head of North America

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIIB Stock Analysis - Frequently Asked Questions

Should I buy or sell Biogen stock right now?: 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 9 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.
What is Biogen's stock price target for 2024?: 27 Wall Street research analysts have issued 12-month price objectives for Biogen's shares. Their BIIB share price targets range from $213.00 to $373.00. On average, they anticipate the company's stock price to reach $295.58 in the next year. This suggests a possible upside of 53.0% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.
How have BIIB shares performed in 2024?: Biogen's stock was trading at $258.77 on January 1st, 2024. Since then, BIIB shares have decreased by 25.3% and is now trading at $193.18.
View the best growth stocks for 2024 here.
Are investors shorting Biogen?: Biogen saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,550,000 shares, an increase of 33.5% from the March 15th total of 2,660,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.5% of the company's shares are short sold.
View Biogen's Short Interest.
When is Biogen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our BIIB earnings forecast.
How can I listen to Biogen's earnings call?: Biogen will be holding an earnings conference call on Wednesday, April 24th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Biogen's earnings last quarter?: Biogen Inc. (NASDAQ:BIIB) released its earnings results on Tuesday, February, 13th. The biotechnology company reported $2.95 EPS for the quarter, missing analysts' consensus estimates of $3.18 by $0.23. The biotechnology company had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.47 billion. Biogen had a net margin of 11.81% and a trailing twelve-month return on equity of 14.91%. During the same period in the prior year, the business earned $4.05 EPS.
Read the conference call transcript.
What ETFs hold Biogen's stock?: ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), VanEck Biotech ETF (BBH), iShares Neuroscience and Healthcare ETF (IBRN), Subversive Mental Health ETF (SANE), Horizon Kinetics Medical ETF (MEDX), Invesco Pharmaceuticals ETF (PJP), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What guidance has Biogen issued on next quarter's earnings?: Biogen updated its FY24 earnings guidance on Wednesday, April, 24th. The company provided earnings per share (EPS) guidance of $15.00-16.00 for the period, compared to the consensus estimate of $15.49. The company issued revenue guidance of decline low- to mid-single digits, compared to the consensus revenue estimate of $9.47 billion.
What is Michel Vounatsos' approval rating as Biogen's CEO?: 394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.
What other stocks do shareholders of Biogen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).
Who are Biogen's major shareholders?: Biogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.27%), Raymond James & Associates (0.12%), Saratoga Research & Investment Management (0.11%), Grimes & Company Inc. (0.03%), Assenagon Asset Management S.A. (0.03%) and Gateway Investment Advisers LLC (0.03%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Eric K Rowinsky, Ginger Gregory, Priya Singhal and Susan H Alexander.
View institutional ownership trends.
How do I buy shares of Biogen?: Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Biogen have any subsidiaries?: The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More

This page (NASDAQ:BIIB) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biogen (BIIB) Stock Price, News & Analysis

Biogen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biogen Stock (NASDAQ:BIIB)

BIIB Stock Price History

BIIB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BIIB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™